Page last updated: 2024-11-07

kt 5823

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KT 5823: indolocarbazole; activates human neutrophils & fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

KT 5823 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID108152
CHEBI ID85102
SCHEMBL ID16099876
MeSH IDM0198924

Synonyms (29)

Synonym
methyl (15s,16r,18r)-16-methoxy-4,15-dimethyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate
gtpl338
kt 5823, >=85% (hplc), lyophilized powder
kt5823
kt-5823
9-methoxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epxoy-1h,8h,11h-2,7b-11a-triazadibenzo(a,g)cycloocta(cde)-trinden-1-one
c29h25n3o5
9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9r-(9alpha,10beta,12alpha))-
kt 5823
9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9r,10r,12r)-
126643-37-6
wy40bab02w ,
unii-wy40bab02w
9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9s,10r,12r)-
SCHEMBL16099876
CHEBI:85102
methyl (5s,6r,8r)-6-methoxy-5,14-dimethyl-13-oxo-5,6,7,8,14,15-hexahydro-13h-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacene-6-carboxylate
(9s,10r,12r)-2,3,9,10,11,12-hexahyd ro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1h-dii ndolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodi azocine-10-carboxylic acid, methyl ester
HB1316
mfcd09878278
methyl (15s,16r,18r)-16-methoxy-4,15-dimethyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DTXSID40925642
Q27887351
kt5823 - cas 126643-37-6
HY-N6791
CS-0014218
9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9s,10r,12r)-
BK162736
AKOS040741920

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This study provides the first evidence that increased denitrosylation leads to increased bioavailability of NO, independent of NOS activity, to promote sustained angiogenesis."( The release of nitric oxide from S-nitrosothiols promotes angiogenesis.
Ahmad, S; Ahmed, A; Ahmed, S; Al-Ani, B; Cudmore, M; Fujisawa, T; Hewett, PW, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Phorbol dibutyrate (PDB), an activator of protein kinase C, stimulated basal phospholipid methylation and also shifted the dose-response curve for dopamine-stimulated phospholipid methylation to the right by more than an order of magnitude."( Protein kinase C regulates dopamine D4 receptor-mediated phospholipid methylation.
Deth, RC; Sharma, A; Waly, M, 2001
)
0.31
" The cumulative dose-response curve of SMA to NE and Ca2+ after shock was shifted to the right."( The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat.
Liu, L; Xu, J, 2005
)
0.33
" In dose-response measures, NO increased the current stimulated by cAMP injection without altering either apparent cAMP binding affinity or cooperativity of current activation."( Nitric oxide potentiates cAMP-gated cation current in feeding neurons of Pleurobranchaea californica independent of cAMP and cGMP signaling pathways.
Gillette, R; Hatcher, NG; Moroz, LL; Sudlow, LC, 2006
)
0.33
" Using the patch-clamp technique in whole-cell configuration, we showed how l-cis-Diltiazem (a CNG-channel inhibitor) and KT5823 (a PKG inhibitor) decreased significantly the amplitude of macroscopic ion currents in a dose-response manner, and decreased in vitro capacitation."( Capacitation and Ca(2+) influx in spermatozoa: role of CNG channels and protein kinase G.
Cisneros-Mejorado, A; Hernández-Soberanis, L; Islas-Carbajal, MC; Sánchez, D, 2014
)
0.4
" In the present work, using whole-cell patch-clamp techniques in rat retinal slice preparations, we further demonstrate that SKF of higher dosage (50μM) significantly suppressed AMPA receptor (AMPAR)-mediated light-evoked excitatory postsynaptic currents (L-EPSCs) of retinal ON-type GCs (ON GCs), and the effect was reversed by the σR1 antagonist BD1047, suggesting the involvement of σR1."( Activation of the sigma receptor 1 modulates AMPA receptor-mediated light-evoked excitatory postsynaptic currents in rat retinal ganglion cells.
Deng, QQ; Liu, LL; Weng, SJ; Yang, XL; Zhong, YM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of cGMP-dependent protein kinase (EC 2.7.11.12).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
gamma-lactamA lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon.
organic heterooctacyclic compound
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
hemiaminalAny organic amino compound that has an amino group and a hydroxy group attached to the same carbon atom. Hemiaminals are intermediates in the formation of imines by addition of an amine to an aldehyde or ketone; those derived from primary amines are particularly unstable.
indolocarbazoleCompounds based upon an indolo[2,3-a]carbazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2000Molecular pharmacology, Jul, Volume: 58, Issue:1
Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2000Molecular pharmacology, Jul, Volume: 58, Issue:1
Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (312)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's73 (23.40)18.2507
2000's166 (53.21)29.6817
2010's66 (21.15)24.3611
2020's7 (2.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.04 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other316 (99.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]